An advanced microencapsulated system: A platform for optimized oral delivery of antidiabetic drug-bile acid formulations

Pharmaceutical Development and Technology

Volumn 20, Issue 6, 2015, Pages 702-709

  Mooranian, Armin ^a   Negrulj, Rebecca ^a   Mathavan, Sangeetha ^a   Martinez, Jorge ^a   Sciarretta, Jessica ^a   Chen Tan, Nigel ^a   Mukkur, T K ^b   Mikov, Momir ^c,d   Lalic Popovic, Mladena ^c   Stojancevic, Maja ^c,d   Golocorbin Kon, Svetlana ^c,d   Al Salami, Hani ^a  

^a CURTIN UNIVERSITY   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c UNIVERSITY OF NOVI SAD   (Serbia)

^d UNIVERSITY OF MONTENEGRO   (Montenegro)

Author keywords

Artificial cell microencapsulation; Bile acids; Diabetes; Gliclazide

Indexed keywords

ALGINIC ACID; CALCIUM ALGINATE; CHOLIC ACID DERIVATIVE; GLICLAZIDE; ANTIDIABETIC AGENT; CHOLIC ACID; DRUG CARRIER; EXCIPIENT; GLUCURONIC ACID; HEXURONIC ACID; MICROCAPSULE;

ARTICLE; CHEMICAL INTERACTION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; ENERGY DISPERSIVE X RAY SPECTROSCOPY; LABORATORY TEST; MICROCAPSULE; MICROENCAPSULATION; MORPHOLOGY; PRIORITY JOURNAL; ROENTGEN SPECTROSCOPY; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; VISCOSITY; ANIMAL; CHEMISTRY; DIABETES MELLITUS, TYPE 1; ORAL DRUG ADMINISTRATION; PROCEDURES; RAT;

ADMINISTRATION, ORAL; ALGINATES; ANIMALS; CAPSULES; CHOLIC ACID; DIABETES MELLITUS, TYPE 1; DRUG CARRIERS; DRUG COMPOUNDING; EXCIPIENTS; GLICLAZIDE; GLUCURONIC ACID; HEXURONIC ACIDS; HYPOGLYCEMIC AGENTS; RATS;

EID: 84964284549     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2014.915570     Document Type: Article

References (30)

1. Barbeau WE, Bassaganya-Riera J, Hontecillas R. Putting the pieces of the puzzle together - A series of hypotheses on the etiology and pathogenesis of type 1 diabetes. Med Hypotheses 2007; 68: 607-619.
2. Ferrannini E. Insulin resistance versus insulin deficiency in noninsulin- dependent diabetes mellitus: Problems and prospects. Endocr Rev J 1998; 19: 477-490.
3. Al-Salami H, Butt G, Tucker I, Mikov M. Probiotic treatment proceeded by a single dose of bile acid and gliclazide exert the most hypoglycemic effect in Type 1 diabetic rats. Med Hypothesis Res 2008; 4: 93-101.
4. Lalić-Popović M, Vasović V, Milijašević B, et al., Deoxycholic acid as a modifier of the permeation of gliclazide through the blood brain barrier of a rat. J Diabetes Res 2013; 2013: Article ID 598603, 8 pages, doi: 10.1155/2013/598603.
5. Barakat NS, Shazly GA, Almedany AH. Influence of polymer blends on the characterization of gliclazide - encapsulated into poly (epsilon-caprolactone) microparticles. Drug Dev Ind Pharm 2013; 39: 352-362.
6. Mikov M, Al-Salami H, Golocorbin-Kon S, et al. The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokinet 2008; 33: 137-142.
7. Efentakis M, Buckton G. The effect of erosion and swelling on the dissolution of theophylline from low and high viscosity sodium alginate matrices. Pharm Dev Technol 2002; 7: 69-77.
8. Al-Kassas RS, Al-Gohary OM, Al-Faadhel MM. Controlling of systemic absorption of gliclazide through incorporation into alginate beads. Int J Pharm 2007; 341: 230-237.
9. Al-Salami H, Butt G, Tucker I, Mikov M. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find Exp Clin Pharmacol 2008; 30: 107-113.
10. Al-Salami H, Butt G, Tucker I, et al. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet 2009; 34: 43-50.
11. Al-Salami H, Butt G, Tucker I, et al. Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet 2012; 37: 99-108.
12. Prajapati SK, Tripathi P, Ubaidulla U, Anand V. Design and development of gliclazide mucoadhesive microcapsules: In vitro and in vivo evaluation. AAPS PharmSciTech 2008; 9: 224-230.
13. Prajapati VD, Mashru KH, Solanki HK, Jani GK. Development of modified release gliclazide biological macromolecules using natural biodegradable polymers. Int J Biol Macromol 2013; 55: 6-14.
14. Mikov M, Boni NS, Al-Salami H, et al. Pharmacokinetics and hypoglycaemic effect of 3 alpha, 7 alpha-dihydroxy-12-oxo-5betacholanate (MKC) in diabetic rat. FEBS J 2006; 273(s1): 210.
15. Pal D, Nayak AK. Development, optimization, and anti-diabetic activity of gliclazide-loaded alginate-methyl cellulose mucoadhesive microcapsules. AAPS PharmSciTech 2011; 12: 1431-1441.
16. Yang Y, Campanella OH, Hamaker BR, et al. Rheological investigation of alginate chain interactions induced by concentrating calcium cations. Food Hydrocolloids 2013; 30: 26-32.
17. de Celis Alonso B, Rayment P, Ciampi E, et al. NMR relaxometry and rheology of ionic and acid alginate gels. Carbohydr Polym 2010; 82: 663-669.
18. Draget KI, Taylor C. Chemical, physical and biological properties of alginates and their biomedical implications. Food Hydrocolloids 2011; 25: 251-256.
19. Bonino CA, Samorezov JE, Jeon O, et al. Real-time in situ rheology of alginate hydrogel photocrosslinking. Soft Matter 2011; 7: 11510-11517.
20. Pamies R, Schmidt RR, Martínez MdCL, Torre JGdl. The influence of mono and divalent cations on dilute and non-dilute aqueous solutions of sodium alginates. Carbohydr Polym 2010; 80: 248-253.
21. Legrand J, Dumont E, Comiti J, Fayolle F. Diffusion coefficients of ferricyanide ions in polymeric solutions - comparison of different experimental methods. Electrochim Acta 2000; 45: 1791-1803.
22. Desai SR, Dharwadkar SR. Study of polymorphic transformation of ornidazole drug by differential scanning calorimetry and other complementary techniques. Acta Pol Pharm 2008; 65: 409-413.
23. Gill P, Moghadam TT, Ranjbar B. Differential scanning calorimetry techniques: Applications in biology and nanoscience. J Biomol Tech 2010; 21: 167-193.
24. Al-Salami H, Butt G, Fawcett JP, et al. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. Eur J Drug Metab Pharmacokinet 2008; 33: 101-106.
25. Takka S, Cali AG. Bile salt-reinforced alginate-chitosan beads. Pharm Dev Technol 2012; 17: 23-29.
26. Nayak BS, Ghosh SK, Patro KTB. Preparation and characterization of famotidine microcapsule employing mucoadhesive polymers in combination to enhance gastro retention for oral delivery. Int J Pharm Sci 2009; 1: 112-120.
27. Barakat NS, Almurshedi AS. Design and development of gliclazideloaded chitosan microparticles for oral sustained drug delivery: In-vitro/in-vivo evaluation. J Pharm Pharmacol 2011; 63: 169-178.
28. Barakat NS, Almurshedi AS. Design and development of gliclazideloaded chitosan for oral sustained drug delivery: In vitro/in vivo evaluation. J Microencapsul 2011; 28: 122-133.
29. Yang L, Xu Y, Su Y, et al. FT-IR spectroscopic study on the variations of molecular structures of some carboxyl acids induced by free electron laser. Spectrochim Acta A Mol Biomol Spectrosc 2005; 62: 1209-1215.
30. Devi MP, Sekar M, Chamundeswari M, et al. A novel wound dressing material - fibrin-chitosan-sodium alginate composite sheet. Bull Mater Sci 2012; 35: 1157-1163.